Chicago April 22-26, 2017 Four posters feature ATS products at next week’s Experimental Biology meeting. Stop by Booth 462 to find out more!
Targeted Toxins featured at Experimental Biology 2017 Meeting Read More »
A quick update on the pursuit of conditional approval of SP-SAP to treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon
Veterinary Development of Substance P-Saporin (SP-SAP) Read More »